A report by Noemie Bisserbe of the ET gives several probable reasons for Pfizer, Novartis and Merck losing market capitalisation over the past three years, including poor pricing strategies and fewer global product launches.
Elsewhere, at an ET summit on the Indian pharma industry, Dr Swati Piramal projects that by 2010, India will have discovered at least five new drugs, and estimates that the cost of innovating a new drug at home was under USD50 million.
And ‘Nano’ is surely the buzzword of the year in India! Even Kapil Sibal has put his two cents in, of the possibility of replicating the low-cost model in pharma. (The cynic in me refuses to use the word ‘success’, because the model is yet to be tested in the market, even if only in the automobile sector.)